Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:SLXP

Salix Pharmaceuticals (SLXP) Stock Price, News & Analysis

→ Urgent Nvidia Warning (From Altimetry) (Ad)
Free SLXP Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
4.96 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
SLXP stock logo

About Salix Pharmaceuticals Stock (NASDAQ:SLXP)

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

SLXP Stock News Headlines

May 17, 2023 | benzinga.com
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029
April 6, 2023 | bizjournals.com
Pharmaceuticals News
February 19, 2023 | thestreet.com
Why Salix Pharmaceuticals (SLXP) Stock Is Gaining Today
January 7, 2023 | thestreet.com
Salix Pharmaceuticals (SLXP) Stock Closed Lower Today as Valeant Looks to Increase Bid
December 31, 2022 | thestreet.com
Why Salix Pharmaceuticals (SLXP) Stock Is Soaring Today
December 25, 2022 | thestreet.com
Why Salix Pharmaceuticals (SLXP) Stock Is Surging Today
December 23, 2022 | thestreet.com
Valeant Pharmaceuticals (VRX) Stock Surges Today as Analyst Ups Price Target on Salix Deal
September 9, 2022 | marketwatch.com
Bausch Health Says FDA Won't Fully Approve Generic Xifaxan Until 2029
September 4, 2022 | thestreet.com
Salix Acquisition Likely, but at What Price Is Open to Debate
July 28, 2022 | seekingalpha.com
Bausch Health plummets 50% following judge's Xifaxan patent order
July 18, 2022 | thestreet.com
DNDNQ News
June 20, 2022 | markets.businessinsider.com
Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022
June 1, 2022 | thestreet.com
Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble
January 6, 2022 | thestreet.com
Stock Market Today: Futures Jump as Jobs Rebound in September
August 2, 2021 | finance.yahoo.com
Canada's Valeant to buy Salix in $10.1 billion deal
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SLXP
CUSIP
79543510
CIK
1009356
Web
www.salix.com
Phone
+1-919-8621000
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

SLXP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Salix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salix Pharmaceuticals investors own include Allergan (AGN), Baidu (BIDU), Gilead Sciences (GILD), (QIHU) (QIHU), Capri (CPRI), 3D Systems (DDD), Intercept Pharmaceuticals (ICPT), Johnson & Johnson (JNJ) and

This page (NASDAQ:SLXP) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
Does this make you sick?
Allegiance Gold
Urgent Nvidia Warning
Altimetry
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Bill Gates is all about this tiny $2 stock
Timothy Sykes
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing